<DOC>
	<DOCNO>NCT00496405</DOCNO>
	<brief_summary>The endothelial growth factor ( VEGF ) , implied genesis diverse Neovascular disease . In industrialized develop country , main cause blindness diabetic retinopathy . Bevacizumab ( Avastin , genentech , Inc. , San Francisco , California , USA ) drug.In last year use `` off-label '' , ophthalmology field , become popular . This due proven safeness effectiveness treatment diverse ocular disease . A lot speculate systemic absorption Bevacizumab . It reason objective study systematic random revision fellows eye , patient program intravitreal administration Bevacizumab , bilateral macular edema . In way therapeutic value fellow eye bevacizumab determine</brief_summary>
	<brief_title>Unilateral Bevacizumab Bilateral Diabetic Macular Edema</brief_title>
	<detailed_description>Introduction : The endothelial growth factor ( VEGF ) , identify first time liquid ascitis Guinean pig ( 6,7 ) . It dimeric glycoprotein , naturally express epithelial tumor cell ( 1 ) . It 's expression retinal hypoxia ( 9 ) , implied genesis diverse Neovascular disease ( 2,4,8,9,19 ) . The activation VEGF pathway promote endothelial cell growth , increase growth , migration survival exist vasculature produce differentiation migration endothelial mother cell bone marrow towards general circulation ( 4 ) . It also vasculature permeability factor , favor formation vascular fenestration , produce exit liquid protein deposit tissue interstice , favor formation macular edema neovascularisation ( 3,8-10 ) . Its activity mediate two tyrosine relate receptor high affinity : VEGFR 1 ( FLT-1 ) VEGFR 2 ( FLT-2 ) ( 1,9 ) . The FLT-1 promotes cellular proliferation whereas FLT-2 migration interaction cell extracellular matrix ( 4,5,10 ) In industrialized develop country , main cause blindness diabetic retinopathy ( 9 ) . Followed close United States Europe Age relate Macular Degeneration ( 10 ) . The frequent cause loss vision diabetic retinopathy macular edema ( 7 ) . Its incidence 13.9 25.4 % ( 15 ) . It characterize accumulation intraretinal liquid level outer plexiform internal nuclear layer , subsequent thicken macula ( 13,15 ) . The diabetic macular Edema associate high level VEGF vitreous ( 7,8,9 ) . At moment , gold standard treatment proliferative retinopathy laser photocoagulation ( 9 ) . The photocoagulation macular area treatment diffuse focal edema , produce 50 % decrease risk severe visual loss . Nevertheless long-term prognosis continue poor ( 15 ) . The Optical Coherent Tomography ( OCT ) relative new , noninvasive technique ( 12,14 ) , base low frequency interferometry phenomenon . It able provide cross-sectional retinal image ( 11,12,15,17 ) . It resolution 10-15mm . thanks , also able quantitatively measure macular thickness ( 10,12,14,15,17 ) . The measurement obtain system highly reproducible correlate patient visual acuity ( 7,11,14,16,17,19 ) . It useful evaluate vitreous-retinal interface retinal adherence ( 11 ) . In macular edema OCT display low reflectivity image increase retinal thickness ( 11,13 ) . The classification macular edema OCT image , propose Dr. Otani ( 16 ) modify Kang ( 15 ) consist 4 type : Type 1 , thicken fovea homogenous optical reflectivity entire retina . Type 2 , thicken retina noticeable diminution optical reflectivity external layer retina . Type 3 , thicken fovea accumulation subfoveal liquid define border detach retina . Type 3A without foveal traction , 3B foveal traction ( 15 ) . Bevacizumab ( Avastin , genentech , Inc. , San Francisco , California , USA ) drug , approve FDA treatment metastatic colorectal cancer ( 2 ) . It consist humanize monoclonal antibody bind active form VEGF ( 3,18,19 ) , block activity two receptor ( 4 ) . In last year use `` off-label '' , ophthalmology field , become popular . This due proven safeness effectiveness treatment diverse ocular disease ( 2-4,7,20 ) . Within ophthalmic pathology treat successfully Intravitreal administration Bevacizumab , mention different Neovascular pathology ( diabetic Retinopathy ( 9,18 ) , age relate macular degeneration ( 2,4,18 ) ) pathology alter vascular permeability ( macular edema ( 4,7 ) , Central branch retinal vein occlusion ( 3,8,20 ) , central serous choroidopathy ) . In , treatment response characterize improvement visual acuity , decrease macular thickness improvement angiographic pattern ( 8,10 ) . The potential complication use Bevacizumab severe thromboembolic event , arterial hypertension ( 18 ) , epistaxis , proteinuria , hemoptysis , alteration wound heal gastrointestinal bleed ( 4,10 ) . Exposition Problem : A lot speculate systemic absorption Bevacizumab . In study Bascom Palmer Eye Institute , doctor Rosenfeld , Puliafito et al demonstrate effectiveness systemic application Bevacizumab treatment age relate macular degeneration apply dose 5mg/Kg . thus Demonstrating , passage molecule systemic circulation specific tissue eye ( 10 ) . Recently , doctor Bakri team Mayo Clinic Rochester , Minnesota , establish small portion intravitreal bevacizumab able pas systemic circulation ( 1.6 % inject dose ) obtain detectable concentration vitreous fellow eye ( 11.17ng/ml ) week number 4 treatment ( 21 ) . In way , case hospital , report like anecdotal case , Bevacizumab application one eye improvement base pathology fellow eye . It reason objective study systematic random revision fellows eye , patient program intravitreal administration Bevacizumab , bilateral macular edema . In way therapeutic value small concentration reach vitreous fellow eye bevacizumab determine .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient great 30 year old , bilateral diffuse diabetic macular edema , degree diabetic retinopathy program Bevacizumab intravitreal administration one eye . Bilateral macular Thickening , measure OCT 225mm big . Pupil dilatation great 5mm . Patient previous treatment diabetic macular edema . Focal diabetic macular edema macular edema different etiology , besides diabetes . ( uveitis , pseudophakic patient , vitreousretinal traction , CRVO , BRVO , CSC ) . Macular edema 3B patter , measure OCT , accord macular edema classification . Medical history severe thromboembolic event , uncontrolled arterial hypertension , transitory ischemic attack , cardiac stroke , acute cerebral vascular event . Pregnant woman breast feed woman Know allergy Bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Vascular endothelial growth factor .</keyword>
	<keyword>Retinal Thickness</keyword>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Optical Coherent Tomography</keyword>
</DOC>